Výsledky vyhledávání - "Debbie Boldt-Houle"

6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Clinical Signs of Puberty in Children with Central Precocious Puberty

Autor: Debbie Boldt-Houle, Keisha Bird, Stuart Atkinson

Publikováno v: Journal of Pediatric Nursing. 58:114-115

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4be0a4f3984bf45597c4360453d08f9b
https://doi.org/10.1016/j.pedn.2021.03.033

Zobrazit plný text záznamu

MP57-17 POLYMER DELIVERED, SUBCUTANEOUSLY ADMINISTERED LEUPROLIDE ACETATE PROVIDES STABLE AND LONG-TERM DRUG DELIVERY AND TESTOSTERONE SUPPRESSION ACROSS 4 PIVOTAL TRIALS

Autor: Franklin Chu, John A. McLane, Christopher Pieczonka, Stuart Atkinson, Debbie Boldt-Houle

Publikováno v: Journal of Urology. 197

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7556030de6b9c8c52f00e5b3af7cdf7
https://doi.org/10.1016/j.juro.2017.02.1791

Zobrazit plný text záznamu

Late administration of luteinizing hormone-releasing hormone (LHRH) agonists and the impact on testosterone suppression in the real-world management of prostate cancer

Autor: Scott T. Tagawa, Stuart Atkinson, Przemyslaw Twardowski, John A. McLane, Debbie Boldt-Houle, A. Oliver Sartor

Publikováno v: Journal of Clinical Oncology. 37:149-149

149 Background: LHRH agonists are standard for androgen deprivation therapy (ADT) for advanced prostate cancer (PCa). Increasing evidence suggests maintaining very low testosterone (T) levels is desirable and correlate with disease-specific survival.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::69c363cb69129da8aa6404e586eb26a0
https://doi.org/10.1200/jco.2019.37.7_suppl.149

Zobrazit plný text záznamu

Low incidence of microsurges with biodegradable polymer-delivered, subcutaneously-administered leuprolide acetate in prostate cancer patients

Autor: John A. McLane, Stuart Atkinson, Eleni Efstathiou, Debbie Boldt-Houle, A. Oliver Sartor

Publikováno v: Journal of Clinical Oncology. 37:158-158

158 Background: Androgen deprivation therapy is a foundational treatment of advanced prostate cancer (PCa) with the primary objective of suppressing circulating androgens.Consistent drug delivery with long-acting leuprolide acetate (LA) formulations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b113156a38d550e07a1a95b90373b65
https://doi.org/10.1200/jco.2019.37.7_suppl.158

Zobrazit plný text záznamu

Onset and maintenance of testosterone suppression in four pivotal trials of subcutaneously administered leuprolide acetate formulated with in-situ forming polymeric delivery technology

Autor: Stuart Atkinson, John A. McLane, Przemyslaw Twardowski, A. Oliver Sartor, Debbie Boldt-Houle

Publikováno v: Journal of Clinical Oncology. 36:205-205

205 Background: Subcutaneously administered leuprolide acetate (SC-LA) formulated with in-situ forming polymeric delivery technology has demonstrated efficacy in suppressing testosterone (T) levels to achieve and maintain medical castration in patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bbb626b197fadb80446064f9e5f93faa
https://doi.org/10.1200/jco.2018.36.6_suppl.205

Zobrazit plný text záznamu

Testosterone (T) suppression by weight and age groups in four pivotal trials of in-situ forming polymer-delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa)

Autor: Scott T. Tagawa, A. Oliver Sartor, Debbie Boldt-Houle, John A. McLane, Stuart Atkinson

Publikováno v: Journal of Clinical Oncology. 36:172-172

172 Background: In-situ forming polymer-delivered, subcutaneous leuprolide acetate (SC-LA) has previously been shown to suppress serum T levels to ≤20ng/dL in advanced PCa patients. Currently, luteinizing hormone releasing hormone agonists are dose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c0c50516d66bbfd1ad695bb077d8f2f4
https://doi.org/10.1200/jco.2018.36.6_suppl.172

Zobrazit plný text záznamu

Nadir testosterone (T) following in-situ polymer delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa)

Autor: Przemyslaw Twardowski, Stuart Atkinson, Debbie Boldt-Houle, Scott T. Tagawa, John A. McLane

Publikováno v: Journal of Clinical Oncology. 36:204-204

204 Background: Achieving and maintaining T suppression to castration level is the cornerstone of androgen deprivation therapy (ADT) for advanced PCa. Modern assay methodology found median T level after surgical castration to be 15ng/dL; the 2016 Eur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c1b7ff47e8adfdf4a7495538cf9150b
https://doi.org/10.1200/jco.2018.36.6_suppl.204

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání